CAPITAL SOLEIL 15 Drug Patent Profile
✉ Email this page to a colleague
When do Capital Soleil 15 patents expire, and what generic alternatives are available?
Capital Soleil 15 is a drug marketed by Loreal Usa and is included in one NDA.
The generic ingredient in CAPITAL SOLEIL 15 is avobenzone; ecamsule; octocrylene. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the avobenzone; ecamsule; octocrylene profile page.
Summary for CAPITAL SOLEIL 15
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CAPITAL SOLEIL 15 at DailyMed |
US Patents and Regulatory Information for CAPITAL SOLEIL 15
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Loreal Usa | CAPITAL SOLEIL 15 | avobenzone; ecamsule; octocrylene | CREAM;TOPICAL | 021501-001 | Oct 2, 2006 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |